-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The BD trading activities of Chinese biopharmaceutical companies have become more active, attracting more and more attention at home and abroad
BD transactions are also an important means for pharmaceutical companies to implement internationalization strategies.
Japan and South Korea are China's neighbors in Asia, and they are also relatively important pharmaceutical markets in Asia, and their internationalization is relatively successful.
illustrate:
illustrate:1) There may be some omissions in the pharmaceutical transaction cases of Japan and South Korea
1) There may be some omissions in the pharmaceutical transaction cases of Japan and South Korea
2) The transaction items include traditionally defined drugs, such as chemical drugs and biological products, including some micro-innovation and biosimilar drugs, but do not include medical device products; early technical cooperation is also included in the scope of statistics
3) Does not include CMO foundry category, CRO category;
3) Does not include CMO foundry category, CRO category;4) According to the official publicly disclosed information, the amount involved is the amount disclosed in the transaction
4) According to the official publicly disclosed information, the amount involved is the amount disclosed in the transactionFirst of all, from the perspective of the number of cross-border transactions, the early trading activity of Chinese companies is less than that of Japanese companies, but the number of transactions has increased sharply since 2018, and the activity has far surpassed that of Japanese and Korean companies.
From the perspective of authorized and introduced enterprises, Chinese enterprises mainly have frequent transactions with American enterprises, and the number of innovative drug products going overseas has increased since 2018.
Japanese companies also have frequent transactions with American companies, while transactions with Chinese companies have increased since 2016
South Korean companies have mainly authorized projects to China, the United States and Japan, and the number of projects introduced from Chinese companies will start to increase in 2020
From the perspective of transaction targets, Japanese companies reached large-scale transactions earlier and the amount was large; Chinese companies started BD transactions late, but since 2020, they have reached a number of externally authorized transactions; Chinese and Japanese companies have authorized externally authorized projects.
China, Japan and South Korea enterprise drug license in transaction top3
Top3 of drug license out transactions for Chinese, Japanese and Korean companies
The total market value of Chinese pharmaceutical companies currently ranks second in the world and first in Asia.
In short, for the internationalization of innovative drug companies, it is actually a “luxury” thing to set up R&D centers and business teams by yourself.
